| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | -0.088 | 0.02 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.079 | 0.02 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.08 | 0.02 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.074 | 0.02 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | 0.074 | 0.02 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.12 | 0.03 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | 0.12 | 0.03 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | -0.083 | 0.03 |
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | -0.085 | 0.03 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.03 |